Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary

This Executive Summary of the Global Strategy for the Diagnosis, Management, and Prevention of COPD (GOLD) 2017 Report focuses primarily on the revised and novel parts of the document. The most significant changes include: 1) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations; 2) for each of the groups A to D, escalation strategies for pharmacological treatments are proposed; 3) the concept of de-escalation of therapy is introduced in the treatment assessment scheme; 4) nonpharmacologic therapies are comprehensively presented and; 5) the importance of comorbid conditions in managing COPD is reviewed. Read the executive summary of the new @GOLD_COPD 2017 report in the European Respiratory Journal http://ow.ly/XxfD308BDfc

[1]  Michel Wolff,et al.  Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. , 2017, The Cochrane database of systematic reviews.

[2]  R. Wood‐Baker,et al.  Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial , 2010, BMJ : British Medical Journal.

[3]  R. Stockley,et al.  Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. , 2000, Chest.

[4]  Charlotte Suppli Ulrik,et al.  Effect of tele health care on exacerbations and hospital admissions in patients with chronic obstructive pulmonary disease: a randomized clinical trial , 2015, International journal of chronic obstructive pulmonary disease.

[5]  B. Celli,et al.  Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. , 2015, American journal of respiratory and critical care medicine.

[6]  D. Mannino,et al.  Lung function impairment, COPD hospitalisations and subsequent mortality , 2011, Thorax.

[7]  N. Chavannes,et al.  Effectiveness of integrated disease management for primary care chronic obstructive pulmonary disease patients: results of cluster randomised trial , 2014, BMJ : British Medical Journal.

[8]  P. Lange,et al.  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.

[9]  H. Reddel,et al.  American Thoracic Society , 2001 .

[10]  D. Mannino,et al.  Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998-2008. , 2012, American journal of respiratory and critical care medicine.

[11]  C. Cates,et al.  Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.

[12]  R. Cumming,et al.  Use of inhaled and oral corticosteroids and the long-term risk of cataract. , 2009, Ophthalmology.

[13]  Christopher E Brightling,et al.  Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. , 2012, American journal of respiratory and critical care medicine.

[14]  B. Lipworth,et al.  Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. , 2014, The Lancet. Respiratory medicine.

[15]  P. Calverley,et al.  Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial , 2005, Thorax.

[16]  M. Cazzola,et al.  Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis , 2015, European Respiratory Review.

[17]  F. Martinez,et al.  Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. , 2013, The Lancet. Respiratory medicine.

[18]  V. Tirlapur Relationship of ventricular ectopy to nocturnal oxygen desaturation in patients with chronic obstructive pulmonary disease. , 1985, The American journal of medicine.

[19]  D. Jarvis,et al.  Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. , 2011, American journal of respiratory and critical care medicine.

[20]  Ø. Borgan,et al.  Lung transplantation in patients with chronic obstructive pulmonary disease in a national cohort is without obvious survival benefit. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[21]  K. Chapman,et al.  Physician perceptions and management of COPD. , 1993, Chest.

[22]  G. Criner,et al.  Home non-invasive ventilation use following acute hypercapnic respiratory failure in COPD. , 2014, Respiratory medicine.

[23]  S. Rennard,et al.  The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[24]  B. Celli,et al.  Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.

[25]  G. Kirk,et al.  HIV-associated obstructive lung diseases: insights and implications for the clinician. , 2014, The Lancet. Respiratory medicine.

[26]  F. Maltais,et al.  Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. , 2002, American journal of respiratory and critical care medicine.

[27]  D. Postma,et al.  Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. , 1999, The New England journal of medicine.

[28]  N. Zhong,et al.  Positive benefits of theophylline in a randomized, double‐blind, parallel‐group, placebo‐controlled study of low‐dose, slow‐release theophylline in the treatment of COPD for 1 year , 2006, Respirology.

[29]  N. Maimon,et al.  The Association Between Hospital Readmission and Pulmonologist Follow-up Visits in Patients With COPD. , 2015, Chest.

[30]  T. Omachi,et al.  Influence of anxiety on health outcomes in COPD , 2010, Thorax.

[31]  G. Marks,et al.  Tuberculosis and chronic respiratory disease: a systematic review. , 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[32]  Meilan K. Han,et al.  Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. , 2014, The New England journal of medicine.

[33]  E. Wouters,et al.  Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. , 1993, The American review of respiratory disease.

[34]  Niels H Chavannes,et al.  Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. , 2009, American journal of respiratory and critical care medicine.

[35]  A. Melani Long-acting muscarinic antagonists , 2015, Expert review of clinical pharmacology.

[36]  P. Calverley,et al.  Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.

[37]  C. Bullen,et al.  Electronic cigarettes for smoking cessation and reduction. , 2014, The Cochrane database of systematic reviews.

[38]  E. Salpeter,et al.  Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. , 2004, Chest.

[39]  A. Torres,et al.  Guidelines for the management of adult lower respiratory tract infections , 2005, European Respiratory Journal.

[40]  C. Husten,et al.  How to help your patients stop smoking. , 1978, American family physician.

[41]  M. Miravitlles,et al.  Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis , 2011, European Respiratory Journal.

[42]  D. Lawlor,et al.  Association of birth weight with adult lung function: findings from the British Women’s Heart and Health Study and a meta-analysis , 2005, Thorax.

[43]  Dennis Emralino Dantic,et al.  A critical review of the effectiveness of ‘teach-back’ technique in teaching COPD patients self-management using respiratory inhalers , 2014 .

[44]  J. Bourbeau,et al.  Clinical Relevance of Fixed Ratio vs Lower Limit of Normal of FEV1/FVC in COPD: Patient-Reported Outcomes From the CanCOLD Cohort , 2015, The Annals of Family Medicine.

[45]  R. Casaburi,et al.  Phenotype of Spirometric Impairment in an Aging Population. , 2016, American journal of respiratory and critical care medicine.

[46]  I. Smith,et al.  The Effects of Withdrawing Long-Term Nocturnal Non-Invasive Ventilation in COPD Patients , 2010, COPD.

[47]  J. Soriano,et al.  Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index. , 2014, Chest.

[48]  S. Glantz,et al.  E-cigarettes and smoking cessation - Authors' reply. , 2016, The Lancet. Respiratory medicine.

[49]  B. Make,et al.  Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD , 2004, European Respiratory Journal.

[50]  Y. Hasegawa,et al.  COPD and disease-specific health status in a working population , 2013, Respiratory Research.

[51]  M. Polkey,et al.  Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (The BeLieVeR-HIFi trial): study design and rationale , 2014, Thorax.

[52]  J. Wedzicha,et al.  Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis , 2003, BMJ : British Medical Journal.

[53]  O. Keene,et al.  Temporal clustering of exacerbations in chronic obstructive pulmonary disease. , 2010, American journal of respiratory and critical care medicine.

[54]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[55]  T. Lasserson,et al.  Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.

[56]  J. Bourbeau,et al.  Tiotropium for stable chronic obstructive pulmonary disease , 2005 .

[57]  John Connett,et al.  Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[58]  Dave Singh,et al.  Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. , 2015, Respiratory medicine.

[59]  Michael C. Fiore,et al.  A Clinical Practice Guideline for Treating Tobacco Use and Dependence A US Public Health Service Report , 2000 .

[60]  M. Martínez-García,et al.  Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[61]  M. Cazzola,et al.  The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. , 2010, Pulmonary pharmacology & therapeutics.

[62]  P. Jones,et al.  Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease , 1999, Thorax.

[63]  F. Martinez,et al.  The National Emphysema Treatment Trial (NETT) Part II: Lessons learned about lung volume reduction surgery. , 2011, American journal of respiratory and critical care medicine.

[64]  K. Rabe,et al.  Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. , 2016, American journal of respiratory and critical care medicine.

[65]  J. Soriano,et al.  Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. , 2010, American journal of respiratory and critical care medicine.

[66]  T. Seemungal,et al.  COPD exacerbations: defining their cause and prevention , 2007, The Lancet.

[67]  R. Murray,et al.  Smoking cessation in chronic obstructive pulmonary disease. , 2009, Respiratory medicine.

[68]  C. Jiang,et al.  Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study , 2007, The Lancet.

[69]  D. Niewoehner,et al.  Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. , 2012, Respiratory medicine.

[70]  Stefan Störk,et al.  "GOLD or lower limit of normal definition? a comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study" , 2012, Respiratory Research.

[71]  R. Casaburi,et al.  Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients , 2008, International journal of chronic obstructive pulmonary disease.

[72]  F. Martinez,et al.  Effect of Ro fl umilast and InhaledCorticosteroid / Long-Acting b 2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations ( RE 2 SPOND ) A Randomized Clinical Trial , 2016 .

[73]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[74]  S. K. Chhabra,et al.  Chronic obstructive pulmonary disease and cardiovascular disease. , 2006, The Indian journal of chest diseases & allied sciences.

[75]  Robert West,et al.  Association between electronic cigarette use and changes in quit attempts, success of quit attempts, use of smoking cessation pharmacotherapy, and use of stop smoking services in England: time series analysis of population trends , 2016, British Medical Journal.

[76]  D. Price,et al.  Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study , 2014, Respiratory Research.

[77]  F. Herrmann,et al.  Can early introduction of specialized palliative care limit intensive care, emergency and hospital admissions in patients with severe and very severe COPD? a randomized study , 2014, BMC Palliative Care.

[78]  F. Maltais,et al.  Aerobic and strength training in patients with chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[79]  F. Martinez,et al.  Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial , 2015, The Lancet.

[80]  J. Brophy,et al.  Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. , 2012, Chest.

[81]  S. Johnston,et al.  Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. , 2006, American journal of respiratory and critical care medicine.

[82]  R. D. de Haan,et al.  Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. , 2010, Journal of aerosol medicine and pulmonary drug delivery.

[83]  Steven Piantadosi,et al.  Patients at high risk of death after lung-volume-reduction surgery. , 2001, The New England journal of medicine.

[84]  Edwin K Silverman,et al.  Characterisation of COPD heterogeneity in the ECLIPSE cohort , 2010, Respiratory research.

[85]  J. Krieger,et al.  Daytime pulmonary hypertension in patients with obstructive sleep apnea syndrome. , 1988, The American review of respiratory disease.

[86]  James D. Chalmers,et al.  Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. , 2013, Annals of the American Thoracic Society.

[87]  N. Hill,et al.  Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. , 1995, American journal of respiratory and critical care medicine.

[88]  L. Davies,et al.  Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial , 1999, The Lancet.

[89]  Steven Piantadosi,et al.  A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. , 2003, The New England journal of medicine.

[90]  A. Rahmel,et al.  The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[91]  R. Casaburi,et al.  Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. , 2005, Chest.

[92]  J. Maurer Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone-Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease: A Randomized Trial , 2008 .

[93]  J. Wedzicha,et al.  Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial , 2010, Respiratory research.

[94]  J. E. Hansen,et al.  Counterpoint: Is an increase in FEV₁ and/or FVC ≥ 12% of control and ≥ 200 mL the best way to assess positive bronchodilator response? No. , 2014, Chest.

[95]  D. Mannino,et al.  The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. , 2009, American journal of respiratory and critical care medicine.

[96]  F. Martinez,et al.  Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials , 2009, The Lancet.

[97]  T. Lasserson,et al.  Lung volume reduction surgery for diffuse emphysema. , 2000, The Cochrane database of systematic reviews.

[98]  K. Porter Hospital and Medical School Planning , 1962 .

[99]  C. Marquette,et al.  Lung Volume Reduction Coil Treatment vs Usual Care in Patients With Severe Emphysema: The REVOLENS Randomized Clinical Trial. , 2016, JAMA.

[100]  J. M. FitzGerald,et al.  Bronchodilator delivery in acute airflow obstruction. A meta-analysis. , 1997, Archives of internal medicine.

[101]  David O Wilson,et al.  Quantitative Computed Tomography Analysis, Airflow Obstruction, and Lung Cancer in the Pittsburgh Lung Screening Study , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[102]  Jun She,et al.  Chinese water-pipe smoking and the risk of COPD. , 2014, Chest.

[103]  R. Casaburi,et al.  Phenotype of normal spirometry in an aging population. , 2015, American journal of respiratory and critical care medicine.

[104]  T. Ng,et al.  Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. , 2007, Archives of internal medicine.

[105]  P. Frith,et al.  Self management for patients with chronic obstructive pulmonary disease. , 2014, The Cochrane database of systematic reviews.

[106]  F. Struik Chronic non-invasive ventilation in COPD: where do we stand? , 2015 .

[107]  T. Bregenzer,et al.  Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. , 2009, JAMA.

[108]  T. Michele,et al.  The safety of tiotropium--the FDA's conclusions. , 2010, The New England journal of medicine.

[109]  P. J. Barnes,et al.  Systemic manifestations and comorbidities of COPD , 2009, European Respiratory Journal.

[110]  J. Wedzicha,et al.  Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. , 2013, The Lancet. Respiratory medicine.

[111]  W. Stalman,et al.  Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, The Netherlands. , 1998, Journal of epidemiology and community health.

[112]  A. Crockett,et al.  Domiciliary oxygen for chronic obstructive pulmonary disease. , 2005, The Cochrane database of systematic reviews.

[113]  P. Poole,et al.  Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. , 2019, The Cochrane database of systematic reviews.

[114]  T. Meyer,et al.  Noninvasive Positive Pressure Ventilation To Treat Respiratory Failure , 1994, Annals of Internal Medicine.

[115]  Edwin K Silverman,et al.  GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. , 2013, The Lancet. Respiratory medicine.

[116]  Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. , 1997, Bulletin of the World Health Organization.

[117]  D. Halpin,et al.  Palliative and end-of-life care for patients with respiratory disease , 2009 .

[118]  D. Postma,et al.  Chronic obstructive pulmonary disease. , 2002, Clinical evidence.

[119]  B. Celli,et al.  Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. , 2006, Chest.

[120]  M. Briel,et al.  Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. , 2013, JAMA.

[121]  W. Dejsomritrutai,et al.  Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. , 2004, Chest.

[122]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[123]  D. Postma,et al.  Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial , 2005, Thorax.

[124]  R. Rodríguez-Roisín,et al.  Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. , 1998, American journal of respiratory and critical care medicine.

[125]  W. Bailey,et al.  Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. , 1995, JAMA.

[126]  M. Miravitlles,et al.  Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. , 1999, Chest.

[127]  A. Høiseth,et al.  Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease , 2011, Thorax.

[128]  tefan,et al.  LONG-TERM TREATMENT WITH INHALED BUDESONIDE IN PERSONS WITH MILD CHRONIC OBSTRUCTIVE PULMONARY DISEASE WHO CONTINUE SMOKING , 2000 .

[129]  Alice M Turner,et al.  Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. , 2015, The Lancet. Respiratory medicine.

[130]  N. Metzdorf,et al.  Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial , 2014, BMC Pulmonary Medicine.

[131]  B. Nordestgaard,et al.  Characteristics and outcomes of chronic obstructive pulmonary disease in never smokers in Denmark: a prospective population study. , 2013, The Lancet. Respiratory medicine.

[132]  G. Washko,et al.  A randomised trial of lung sealant versus medical therapy for advanced emphysema , 2015, European Respiratory Journal.

[133]  P. Jones,et al.  Health status measurement in chronic obstructive pulmonary disease , 2001, Thorax.

[134]  Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis. , 1965, Lancet.

[135]  M. Wysocki,et al.  Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. , 1995, The New England journal of medicine.

[136]  R. Zuwallack,et al.  Salmeterol plus theophylline combination therapy in the treatment of COPD. , 2001, Chest.

[137]  R. Masterton,et al.  Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. , 2001, International journal of antimicrobial agents.

[138]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[139]  R. Ferrence,et al.  Electronic Cigarettes for Smoking Cessation: A Systematic Review. , 2016, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[140]  Berend C Stoel,et al.  Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[141]  Meilan K. Han,et al.  Pulmonary arterial enlargement and acute exacerbations of COPD. , 2012, The New England journal of medicine.

[142]  K. Godfrey,et al.  Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. , 1991, BMJ.

[143]  N. Anthonisen,et al.  Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.

[144]  Gordon H. Guyatt,et al.  Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care , 2010, Canadian Medical Association Journal.

[145]  Christopher E Brightling,et al.  Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. , 2011, American journal of respiratory and critical care medicine.

[146]  G. Valdivia,et al.  Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America , 2007, European Respiratory Journal.

[147]  M. Tsukino,et al.  Predictive properties of different multidimensional staging systems in patients with chronic obstructive pulmonary disease , 2011, International journal of chronic obstructive pulmonary disease.

[148]  P. Poole,et al.  Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. , 2013, The Cochrane database of systematic reviews.

[149]  Dirkje S Postma,et al.  Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study , 2000, The Lancet.

[150]  E. Kerwin,et al.  Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies , 2015, COPD.

[151]  B. Rowe,et al.  Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials , 2003, BMJ : British Medical Journal.

[152]  J. Curtis,et al.  Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease , 2006, Expert review of anti-infective therapy.

[153]  R. Hancox,et al.  Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. , 2016, The Lancet. Respiratory medicine.

[154]  P. Bower,et al.  Effect of telehealth on quality of life and psychological outcomes over 12 months (Whole Systems Demonstrator telehealth questionnaire study): nested study of patient reported outcomes in a pragmatic, cluster randomised controlled trial , 2013, BMJ : British Medical Journal.

[155]  T. Lasserson,et al.  Inhaled corticosteroids for stable chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.

[156]  S. Parthasarathy,et al.  Retrospective Assessment of Home Ventilation to Reduce Rehospitalization in Chronic Obstructive Pulmonary Disease. , 2015, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[157]  D. Postma,et al.  Relapse in FEV1 Decline After Steroid Withdrawal in COPD. , 2015, Chest.

[158]  J. Garcia-Aymerich,et al.  Wood smoke exposure and risk of chronic obstructive pulmonary disease , 2006, European Respiratory Journal.

[159]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[160]  R. Hoogenveen,et al.  Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach , 2010, European Respiratory Journal.

[161]  Martijn A Spruit,et al.  Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[162]  Thomas R Fanshawe,et al.  Combined pharmacotherapy and behavioural interventions for smoking cessation. , 2016, The Cochrane database of systematic reviews.

[163]  F. Abroug,et al.  Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial , 2001, The Lancet.

[164]  J. Connett,et al.  Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. , 1996, American journal of respiratory and critical care medicine.

[165]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[166]  E. A. V. van Eerd,et al.  Smoking cessation for people with chronic obstructive pulmonary disease. , 2016, The Cochrane database of systematic reviews.

[167]  J. Barberà,et al.  Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease , 1996, The Lancet.

[168]  M. Fiore A Clinical Practice Guideline for Treating Tobacco Use and Dependence A US Public Health Service Report , 2000 .

[169]  Ulrike Held,et al.  Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index , 2009, The Lancet.

[170]  L. Fabbri,et al.  Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents , 2010, Respiratory research.

[171]  J. Hokanson,et al.  The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. , 2011, Chest.

[172]  J. Wedzicha,et al.  Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.

[173]  A. Anzueto,et al.  Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. , 2011, Archives of internal medicine.

[174]  Stephanie J. C. Taylor,et al.  Withdrawal of inhaled corticosteroids in individuals with COPD - a systematic review and comment on trial methodology , 2011, Respiratory research.

[175]  Toru Oga,et al.  Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. , 2002, Chest.

[176]  P. Jones,et al.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.

[177]  D. Matamis,et al.  Targeting occult heart failure in intensive care unit patients with acute chronic obstructive pulmonary disease exacerbation: effect on outcome and quality of life. , 2014, Journal of critical care.

[178]  Gorka Bastarrika,et al.  Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. , 2007, Chest.

[179]  J. Bourbeau,et al.  Inhaled tiotropium for stable chronic obstructive pulmonary disease. , 2000, The Cochrane database of systematic reviews.

[180]  P. Frith,et al.  Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study—a randomised controlled trial , 2015, Thorax.

[181]  K. Murphy,et al.  The language of breathlessness. Use of verbal descriptors by patients with cardiopulmonary disease. , 1991, The American review of respiratory disease.

[182]  P. Poole,et al.  Tiotropium versus placebo for chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.

[183]  Meilan K. Han,et al.  Clinical and Radiologic Disease in Smokers With Normal Spirometry. , 2015, JAMA internal medicine.

[184]  P. Anderson,et al.  Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial , 2001, The Lancet.

[185]  Hakan Günen,et al.  Waterpipe tobacco smoking. , 2016, Tuberkuloz ve toraks.

[186]  N. Cox,et al.  Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009 .

[187]  M. Decramer,et al.  Withdrawal of inhaled glucocorticoids and exacerbations of COPD. , 2014, The New England journal of medicine.

[188]  F. Speizer,et al.  The relationship of nonspecific bronchial responsiveness to respiratory symptoms in a random population sample. , 1987, The American review of respiratory disease.

[189]  Miwako Kobayashi,et al.  Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices , 2019, MMWR. Morbidity and mortality weekly report.

[190]  I. Stiell,et al.  Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. , 2003, The New England journal of medicine.

[191]  F. Martinez,et al.  Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial , 2016, The Lancet.

[192]  R. Rodríguez-Roisín,et al.  Antibiotics for exacerbations of chronic obstructive pulmonary disease. , 2011, The Cochrane database of systematic reviews.

[193]  B. O'connor,et al.  Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD , 2008, Thorax.

[194]  J. Walusiak‐Skorupa,et al.  Faculty Opinions recommendation of COPD in never smokers: results from the population-based burden of obstructive lung disease study. , 2011 .

[195]  F. Martinez,et al.  Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. , 2015, Annals of the American Thoracic Society.

[196]  J. Vestbo,et al.  The prognostic importance of lung function in patients admitted with heart failure , 2010, European journal of heart failure.

[197]  H A Vrooman,et al.  A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. , 1999, American journal of respiratory and critical care medicine.

[198]  W. Vollmer,et al.  Marijuana and chronic obstructive lung disease: a population-based study , 2009, Canadian Medical Association Journal.

[199]  E. Akl,et al.  Effects of water-pipe smoking on lung function: a systematic review and meta-analysis. , 2011, Chest.

[200]  P. Jones,et al.  Oral theophylline for chronic obstructive pulmonary disease. , 2002, The Cochrane database of systematic reviews.

[201]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[202]  J. Kai,et al.  A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial. , 2015, Health technology assessment.

[203]  Y. Kim,et al.  The Effectiveness of Anti-leukotriene Agents in Patients with COPD: A Systemic Review and Meta-analysis , 2015, Lung.

[204]  G. Michaud,et al.  Effect of Endobronchial Coils vs Usual Care on Exercise Tolerance in Patients With Severe Emphysema: The RENEW Randomized Clinical Trial. , 2016, JAMA.

[205]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[206]  R. Cavallazzi,et al.  Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies , 2011, Thorax.

[207]  Andrew J. White,et al.  Chronic obstructive pulmonary disease • 6: The aetiology of exacerbations of chronic obstructive pulmonary disease , 2003, Thorax.

[208]  M. Ezzati Indoor air pollution and health in developing countries , 2005, The Lancet.

[209]  J. Yim,et al.  Use of inhaled corticosteroids and the risk of tuberculosis , 2013, Thorax.

[210]  A. Anzueto,et al.  Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. , 2000, Chest.

[211]  J. Wedzicha,et al.  Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.

[212]  Hospice National Consensus Project for Quality Palliative Care: Clinical Practice Guidelines for quality palliative care, executive summary. , 2004, Journal of palliative medicine.

[213]  J. Wedzicha,et al.  Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. , 2016, The New England journal of medicine.

[214]  P. Davies,et al.  Tuberculosis, bronchiectasis and chronic airflow obstruction , 2010, Respirology.

[215]  Stephan von Haehling,et al.  Cachexia as a major underestimated and unmet medical need: facts and numbers , 2010, Journal of cachexia, sarcopenia and muscle.

[216]  M. Decramer,et al.  High Doses of Vitamin D to Reduce Exacerbations in Chronic Obstructive Pulmonary Disease: A Randomized Trial , 2012 .

[217]  Hayden McRobbie,et al.  E-cigarettes: an evidence update. A report commissioned by Public Health England. , 2015 .

[218]  Shaf Keshavjee,et al.  A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[219]  D. Mannino,et al.  International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study , 2007, The Lancet.

[220]  T. Lasserson,et al.  Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.

[221]  Robert Paine,et al.  Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. , 2016, The New England journal of medicine.

[222]  K. Rabe,et al.  Complex chronic comorbidities of COPD , 2008, European Respiratory Journal.

[223]  A. Schols,et al.  The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review , 2016, COPD.

[224]  J. Soriano,et al.  Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities , 2009, Thorax.

[225]  David G. Anderson,et al.  Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[226]  D. Mannino,et al.  Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD , 2008, European Respiratory Journal.

[227]  J. Hallas,et al.  Gastro‐esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease , 2015, Respirology.

[228]  A. Hansell,et al.  Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. , 2005, Chest.

[229]  G. Pledger,et al.  Tiotropium Respimat inhaler and the risk of death in COPD. , 2013, The New England journal of medicine.

[230]  E. Regan,et al.  Impact of self-reported Gastroesophageal reflux disease in subjects from COPDGene cohort , 2014, Respiratory Research.

[231]  R. Sansores,et al.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[232]  G. Zeng,et al.  Protective effect of a bacterial extract against acute exacerbation in patients with chronic bronchitis accompanied by chronic obstructive pulmonary disease. , 2004, Chinese medical journal.

[233]  M. Decramer,et al.  Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study , 2013, European Respiratory Journal.

[234]  G. Diette,et al.  Occupational exposures are associated with worse morbidity in patients with chronic obstructive pulmonary disease. , 2015, American journal of respiratory and critical care medicine.

[235]  C. Jenkins,et al.  Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. , 2009, Chest.

[236]  I. Tager,et al.  Maternal smoking during pregnancy. Effects on lung function during the first 18 months of life. , 1995, American journal of respiratory and critical care medicine.

[237]  P. Plant,et al.  Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial , 2000, The Lancet.

[238]  T. Troosters,et al.  Increasing implementation and delivery of pulmonary rehabilitation: key messages from the new ATS/ERS policy statement , 2016, European Respiratory Journal.

[239]  M. Cazzola,et al.  Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. , 2012, Primary care respiratory journal : journal of the General Practice Airways Group.

[240]  Eliane Cristina Zacarias,et al.  Efeito da teofilina associada ao beta2-agonista inalatório de curta ou longa duração, em pacientes com doença pulmonar obstrutiva crônica estável: revisão sistemática , 2007 .

[241]  Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation--a consensus conference report. , 1999, Chest.

[242]  H. Tange,et al.  Early detection of COPD in general practice: implementation, workload and socioeconomic status. A mixed methods observational study , 2013, Primary Care Respiratory Journal: Journal of the General Practice Airways Group.

[243]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[244]  L. Edwards,et al.  Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. , 2013, Respiratory medicine.

[245]  E. V. van Rikxoort,et al.  Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation. , 2015, The New England journal of medicine.

[246]  R. Ferrari,et al.  Impact of a recent hospitalization on treatment and prognosis of ST-segment elevation myocardial infarction. , 2013, International journal of cardiology.

[247]  N. Team Chronic obstructive pulmonary disease in over 16s: diagnosis and management , 2018 .

[248]  K. Nichol,et al.  The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. , 1994, The New England journal of medicine.

[249]  M. Hamarshi,et al.  Accuracy of Clinical Scores and Antibody Testing in the Diagnosis of HIT , 2012 .

[250]  Brian J Smith,et al.  Lung volume reduction surgery for diffuse emphysema. , 2016, The Cochrane database of systematic reviews.

[251]  C. Whitney,et al.  Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2014, MMWR. Morbidity and mortality weekly report.

[252]  A. Corrado,et al.  The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients , 2002, European Respiratory Journal.

[253]  Michael Brauer,et al.  Associations of ambient air pollution with chronic obstructive pulmonary disease hospitalization and mortality. , 2013, American journal of respiratory and critical care medicine.

[254]  N. Chavannes,et al.  Integrated disease management interventions for patients with chronic obstructive pulmonary disease. , 2013, The Cochrane database of systematic reviews.

[255]  R. Stockley,et al.  Augmentation Therapy for α1 Antitrypsin Deficiency: A Meta-Analysis , 2009, COPD.

[256]  Phung Anh Nguyen,et al.  Influenza vaccination and reduction in risk of ischemic heart disease among chronic obstructive pulmonary elderly , 2013, Comput. Methods Programs Biomed..

[257]  N. Anthonisen,et al.  Mortality in COPD: role of comorbidities , 2006, European Respiratory Journal.

[258]  A. Ionescu,et al.  What community measurements can be used to predict bone disease in patients with COPD? , 2008, Respiratory medicine.

[259]  C. Roberts,et al.  Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit , 2015, European Respiratory Journal.

[260]  S. Ginsburg,et al.  Bronchodilator Delivery in Acute Airflow Obstruction , 2017 .

[261]  K. Rabe,et al.  Tiotropium versus salmeterol for the prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[262]  David M. Shade,et al.  A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. , 2016, The New England journal of medicine.

[263]  B. Smith,et al.  Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. , 2006, The Cochrane database of systematic reviews.

[264]  T. Seemungal,et al.  Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. , 2008, American journal of respiratory and critical care medicine.

[265]  M. Antonelli,et al.  Noninvasive vs. conventional mechanical ventilation in patients with chronic obstructive pulmonary disease after failure of medical treatment in the ward: a randomized trial , 2002, Intensive Care Medicine.

[266]  Philippe Ravaud,et al.  Survival after bilateral versus single lung transplantation for patients with chronic obstructive pulmonary disease: a retrospective analysis of registry data , 2008, The Lancet.

[267]  W. Dupont,et al.  A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. , 1994, The Journal of infectious diseases.

[268]  P. Calverley,et al.  Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.

[269]  A. Ionescu,et al.  Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.

[270]  J. Bourbeau,et al.  Tiotropium in Combination with Placebo, Salmeterol, or FluticasoneSalmeterol for Treatment of Chronic Obstructive Pulmonary Disease , 2007, Annals of Internal Medicine.

[271]  S. Suissa,et al.  Inhaled corticosteroids and the risks of diabetes onset and progression. , 2010, The American journal of medicine.

[272]  I. Pavord,et al.  Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. , 2015, The Lancet. Respiratory medicine.

[273]  J. Barberà,et al.  Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial , 2013, European Respiratory Journal.

[274]  K. N. Maranetra,et al.  Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients. , 2003, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[275]  M. V. Lopez Varela,et al.  Development of a simple screening tool for opportunistic COPD case finding in primary care in Latin America: The PUMA study , 2016, Respirology.

[276]  D. Simel,et al.  Does the clinical examination predict airflow limitation? , 1995, JAMA.

[277]  Anne Holland,et al.  Pulmonary Rehabilitation Exercise Prescription in Chronic Obstructive Pulmonary Disease: Review of Selected Guidelines: AN OFFICIAL STATEMENT FROM THE AMERICAN ASSOCIATION OF CARDIOVASCULAR AND PULMONARY REHABILITATION. , 2016, Journal of cardiopulmonary rehabilitation and prevention.

[278]  L. Edwards,et al.  Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease , 2012, Thorax.

[279]  Stefano Guerra,et al.  Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study , 2007, The Lancet.

[280]  R. Holle,et al.  Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences‐Comorbidities Network Study , 2017, American journal of respiratory and critical care medicine.

[281]  N. Zhong,et al.  Lung Function and Incidence of Chronic Obstructive Pulmonary Disease after Improved Cooking Fuels and Kitchen Ventilation: A 9-Year Prospective Cohort Study , 2014, PLoS medicine.

[282]  Nicolas Roche,et al.  Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. , 2009, Chest.

[283]  R. Perera,et al.  Pharmacological interventions for smoking cessation: an overview and network meta-analysis. , 2013, The Cochrane database of systematic reviews.

[284]  M. Scorsetti,et al.  Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. , 2015, American journal of respiratory and critical care medicine.

[285]  J. Crowley,et al.  Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. , 1996, American journal of respiratory and critical care medicine.

[286]  Dependence Update Panel,et al.  A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. , 2008, American journal of preventive medicine.

[287]  Y. Lacasse,et al.  Nocturnal noninvasive positive pressure ventilation in stable COPD: a systematic review and individual patient data meta-analysis. , 2014, Respiratory medicine.

[288]  H. Hoogsteden,et al.  Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. , 2014, The Lancet. Respiratory medicine.

[289]  J. Collet,et al.  Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. , 1997, American journal of respiratory and critical care medicine.

[290]  Dave Singh,et al.  Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial , 2016, The Lancet.

[291]  J. Hallas,et al.  Statin use and exacerbations in individuals with chronic obstructive pulmonary disease , 2014, Thorax.

[292]  Edwin K Silverman,et al.  Reduced Bone Density and Vertebral Fractures in Smokers. Men and COPD Patients at Increased Risk. , 2015, Annals of the American Thoracic Society.

[293]  H. Sørensen,et al.  Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis , 2012, Thorax.

[294]  P. Enright,et al.  Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications , 2012, Thorax.

[295]  S. D. Lee,et al.  Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. , 2012, Respiratory medicine.

[296]  E. Bateman,et al.  Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT) , 2015, Respiratory Research.

[297]  Y. Oh,et al.  Lung function decline rates according to GOLD group in patients with chronic obstructive pulmonary disease , 2015, International journal of chronic obstructive pulmonary disease.

[298]  C. Bausewein,et al.  Levodropropizine in the Management of Cough Associated with Cancer or Nonmalignant Chronic Disease–A Systematic Review , 2011, Journal of pain & palliative care pharmacotherapy.

[299]  G. Guyatt,et al.  A measure of quality of life for clinical trials in chronic lung disease. , 1987, Thorax.

[300]  T. Seemungal,et al.  Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[301]  J. Vonk,et al.  Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study , 2014, Thorax.

[302]  N. Roche,et al.  High-risk patients following hospitalisation for an acute exacerbation of COPD , 2013, European Respiratory Journal.

[303]  G. Criner,et al.  Surgical Approaches to Treating Emphysema: Lung Volume Reduction Surgery, Bullectomy, and Lung Transplantation , 2015, Seminars in Respiratory and Critical Care Medicine.

[304]  J. Wedzicha,et al.  Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease , 1993, The Lancet.

[305]  A. Dirksen,et al.  Exploring the role of CT densitometry: a randomised study of augmentation therapy in α1-antitrypsin deficiency , 2009, European Respiratory Journal.

[306]  Stefano Guerra,et al.  Asthma as a risk factor for COPD in a longitudinal study. , 2004, Chest.

[307]  J. van der Palen,et al.  Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. , 2002, American journal of respiratory and critical care medicine.

[308]  B. Celli,et al.  Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD. , 2000, Chest.

[309]  R. Wood‐Baker,et al.  Influenza vaccine for patients with chronic obstructive pulmonary disease. , 2006, The Cochrane database of systematic reviews.

[310]  D. Slebos,et al.  Bronchoscopic lung-volume reduction with Exhale airway stents for emphysema (EASE trial): randomised, sham-controlled, multicentre trial , 2011, The Lancet.

[311]  T. Todisco,et al.  Mild prematurity and respiratory functions , 2005, European Journal of Pediatrics.

[312]  S. Antoniu,et al.  Hospitalizations and mortality in the Lung Health Study , 2002, Expert review of pharmacoeconomics & outcomes research.

[313]  Edwin K Silverman,et al.  An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. , 2010, American journal of respiratory and critical care medicine.

[314]  M. Jit,et al.  Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis. , 2015, Health technology assessment.

[315]  S. Leu,et al.  Reply: FEV1 can be associated with reduced values after vigorous exercise in healthy adolescents. , 2015, Annals of the American Thoracic Society.

[316]  M. Puhan,et al.  Mortality of patients with COPD participating in chronic disease management programmes: a happy end? , 2014, Thorax.

[317]  E. Kerwin,et al.  FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.

[318]  C. Cates,et al.  Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. , 2015, The Cochrane database of systematic reviews.

[319]  Stefano Nava,et al.  Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. , 2014, The Lancet. Respiratory medicine.

[320]  H. Moldofsky,et al.  Role of daytime hypoxemia in the pathogenesis of right heart failure in the obstructive sleep apnea syndrome. , 2015, The American review of respiratory disease.

[321]  P. Poole,et al.  Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. , 2017, The Cochrane database of systematic reviews.

[322]  Grant D. Huang,et al.  A Comprehensive Care Management Program to Prevent Chronic Obstructive Pulmonary Disease Hospitalizations , 2012, Annals of Internal Medicine.

[323]  A. Thomson,et al.  Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. , 1993, Thorax.

[324]  M. Martínez-García,et al.  Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease , 2005, Thorax.

[325]  Sally J. Singh,et al.  An early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease: randomised controlled trial , 2014, BMJ : British Medical Journal.

[326]  D. Au,et al.  A randomized trial to improve communication about end-of-life care among patients with COPD. , 2012, Chest.

[327]  D. Niewoehner,et al.  Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. , 1999, The New England journal of medicine.

[328]  B. Ternestedt,et al.  “The unpredictable death”—The last year of life for patients with advanced COPD: Relatives' stories , 2014, Palliative and Supportive Care.

[329]  David O Wilson,et al.  Association of radiographic emphysema and airflow obstruction with lung cancer. , 2008, American journal of respiratory and critical care medicine.

[330]  S. Rennard,et al.  Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. , 2011, Chest.

[331]  J. Wedzicha,et al.  Beta-blockers in COPD: time for reappraisal , 2016, European Respiratory Journal.

[332]  T. Welte,et al.  Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.

[333]  Thierry Troosters,et al.  An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. , 2013, American journal of respiratory and critical care medicine.

[334]  R. Rodríguez-Roisín,et al.  Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial. , 2016, Chest.

[335]  L. Stead,et al.  Physician advice for smoking cessation. , 2004, The Cochrane database of systematic reviews.

[336]  J. Toral,et al.  Comparison of effects of strength and endurance training in patients with chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[337]  David Gur,et al.  Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. , 2011, American journal of respiratory and critical care medicine.

[338]  C. Nordeen Use of Inhaled Corticosteroids in Patients With COPD and the Risk of TB and Influenza: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2014 .

[339]  O. Johnell,et al.  Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler® , 2002, European Respiratory Journal.

[340]  Y. Kuo,et al.  Association of Psychological Disorders With 30-Day Readmission Rates in Patients With COPD. , 2016, Chest.

[341]  Nicola A Hanania,et al.  Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. , 2011, Radiology.

[342]  G. McLennan,et al.  A randomized study of endobronchial valves for advanced emphysema. , 2010, The New England journal of medicine.

[343]  C. Janson,et al.  The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE) index is predictive of mortality in COPD. , 2012, Primary care respiratory journal : journal of the General Practice Airways Group.

[344]  Erratum: reduced bone density and vertebral fractures in smokers. men and COPD patients at increased risk. , 2015, Annals of the American Thoracic Society.

[345]  M. Decramer,et al.  Bronchodilator responsiveness in patients with COPD , 2008, European Respiratory Journal.

[346]  P. Schweitzer,et al.  Relationship of ventricular ectopy to nocturnal oxygen desaturation in patients with chronic obstructive pulmonary disease. , 1985, The American journal of medicine.

[347]  S. Cendon,et al.  Effect of theophylline associated with short-acting or long-acting inhaled beta2-agonists in patients with stable chronic obstructive pulmonary disease: a systematic review. , 2007, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

[348]  P. Kvale,et al.  Predischarge bundle for patients with acute exacerbations of COPD to reduce readmissions and ED visits: a randomized controlled trial. , 2015, Chest.

[349]  M. Velloso,et al.  Evaluation of effects of shoulder girdle training on strength and performance of activities of daily living in patients with chronic obstructive pulmonary disease , 2013, International Journal of COPD.

[350]  D. Postma,et al.  Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. , 2007, Chest.

[351]  J. Steurer,et al.  Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. , 2009, The Cochrane database of systematic reviews.

[352]  P. Jones,et al.  Creating scenarios of the impact of copd and their relationship to copd assessment test (CAT™) scores , 2011, BMC pulmonary medicine.

[353]  C. Jenkins,et al.  Cardiovascular events in patients with COPD: TORCH Study results , 2010, Thorax.

[354]  Sally J. Singh,et al.  Supported self-management for patients with moderate to severe chronic obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis. , 2015, Health technology assessment.

[355]  Marco Lodi,et al.  Inhaler mishandling remains common in real life and is associated with reduced disease control. , 2011, Respiratory medicine.

[356]  M. Decramer,et al.  Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. , 2013, The Lancet. Respiratory medicine.